The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Gynecologic Cancers MORE >>

The combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) has been granted a breakthrough therapy designation by the FDA as a treatment for patients with advanced and/or metastatic non–microsatellite instability high/proficient mismatch repair endometrial carcinoma who have progressed after ≥1 prior systemic therapy. This designation will allow for the expedited development and review of the combination in this setting.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.